Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients
- 424 Downloads
Interleukin-28B (IL-28B) is suspected to be associated with response to treatment and one of the basic immunological backgrounds in liver transplant candidate (LTC). We aimed to assess whether genotypes of IL-28B can play a role in therapeutic response or advanced stages of liver disease. A total of 364 subjects were genotyped for IL-28B rs12979860 and rs8099917 SNPs using PCR-RFLP assay. Moreover, IL-28 serum level, HCV loads, and genotype were performed. A significant increase was observed in the frequencies of unfavorable rs12979860 genotypes/CT + TT in the chronic hepatitis C (CHC) and LTC groups. In the case of rs8099917, CHC group had a significantly higher frequency of unfavorable genotypes/GT + GG compared to the healthy group. IL-28B serum level was also significantly higher in healthy group compared with the CHC and LTC groups. There were no differences in the distribution of the IL-28B genotypes and haplotypes between responder and non-responder patients. Our results suggest, for the first time, that unfavorable rs12979860 genotypes can be considered one of the important immunological backgrounds in the Iranian LTC population that was confirmed with the lower IL-28 serum level compared to healthy group. Besides, there was a possible association of favorable IL-28B genotypes with lower odds of susceptibility to CHC infection but no support for a positive association between analyzed SNPs and an outcome of therapy. Moreover, non-CT haplotypes may be regarded as a genetic risk factor that can increase the chance of infection with HCV and progression toward end-stage HCV-related liver disease.
KeywordsHCV Liver transplant candidate IL-28B Treatment outcome
The authors would like to thank personnel of Digestive Disease Research Institute (DDRI) of Shariati Hospital, affiliated with Tehran University of Medical Sciences for excellent work in collecting blood samples. We also express special thanks to Saeed Ghanbari, Ph.D. Student of Department of Biostatistics, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran, for his statistical assistance and Ali Nasimi (Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran), and Jean Krugman, retired professor of General Studies, DeVry University, Decatur, Georgia, USA, for help in revising the English of the manuscript. This study was financially supported by Iran’s National Elites Foundation, Allame Tabatabai National Award.
Compliance with ethical standards
Conflict of interest
None of the authors has any conflict of interest to disclose.
- 7.Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA et al (2015) Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015:768470CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Hassan MK, Haq MU, Amin M, Nawaz A, Khan HU (2014) Association between baseline parameters and end of treatment response to combination of conventional interferon and ribavirin in patients with chronic Hepatitis C. J Postgrad Med Inst 28(2):149–153Google Scholar
- 9.Aziz H, Raza A, Waheed Y, Gill U, Gill ML (2012) Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Int J Infect Dis 16(8):e597–e602CrossRefPubMedGoogle Scholar
- 10.Lin K-H, Yu H-C, Hsu P-I, Tsai W-L, Chen W-C, Lin C-K et al (2013) Baseline high viral load and unfavorable patterns of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy. Hepat Mon 13(10):e11892CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Ivanova I, Kotsev I, Atanassova M, Atanassova A, Manevska B, Krasnaliev I et al (2013) Baseline viral load-a predictor of treatment response in advanced hepatitis C. Scrip Sci Med 45(3):53–57Google Scholar
- 18.Sharifi A, Haj-Sheykholeslami A, Poustchi H, Golzari R, Merat S, Malekzadeh R et al (2016) Efficacy of locally manufactured Sofosbuvir and Daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis C and cirrhosis in Iran-preliminary report. Govaresh 21(2):93–97Google Scholar
- 26.Jabari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K et al (2011) Pegaferon in hepatitis C: results of a multicenter study. Middle East J Dig Dis 3(2):110–114Google Scholar
- 27.Heidar S, Ali P, Bita B, Maryam K, Leila M, Shima S et al (2012) Development and validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon 2012:190–195Google Scholar
- 29.De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A et al (2014) Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int 2014Google Scholar
- 33.Moghaddam MA, Zali MR, Andabili SHA, Derakhshan F, Miri SM, Alavian SM (2012) High rate of virological response to Peginterferon α-2a-Ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iran Red Crescent Med J 14(8):466–473Google Scholar
- 36.Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D et al (2013) Association of IL28B polymorphisms with the response to peginterferon plus ribavirin combined therapy in Polish patients infected with HCV genotype 1 and 4. Hepat Mon 13(11)Google Scholar
- 38.Rashidi R, Toosi MN, Siya RS, Forutan H, Merat S, Daryani NE (2010) The effect of interleukin 28 B polymorphism on sustained virology response (SVR) in patients with chronic hepatitis C. Govaresh 15(3):202–208Google Scholar
- 45.Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K (2012) Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Age 19(80.39):0.05Google Scholar
- 46.Mach T, Ciesla A, Sanak M, Golwacki M, Warunek W (2012) The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b. Prz Gastroenterol 7:38–42Google Scholar
- 55.Tseng C-W, Chen C-Y, Chang T-T, Tzeng S-J, Hsieh Y-H, Hung T-H et al (2014) Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response. PLoS One 9(6):e100207CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J et al (2013) Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol 58(6):1104–1112CrossRefPubMedGoogle Scholar